Welcome to our dedicated page for ImageneBio SEC filings (Ticker: IMA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ImageneBio, Inc. (neBio, Inc., Nasdaq: IMA) SEC filings page on Stock Titan aggregates the company’s U.S. regulatory disclosures, giving investors direct access to official information about this clinical-stage biotechnology issuer. neBio focuses on therapeutics for immunological, autoimmune, and inflammatory diseases, and its filings provide context on the development of its lead asset, -007, an investigational non-depleting anti-OX40 monoclonal antibody.
Through this page, users can review current reports on Form 8-K that document material events such as the completion and subsequent amendment of the merger between Inmagene Biopharmaceuticals and Ikena Oncology, Inc., changes in executive officers and directors, entry into or modification of material agreements, and the announcement of quarterly financial results. These filings also confirm that neBio’s common stock, with a par value of $0.001 per share, is registered under Section 12(b) of the Exchange Act and trades on The Nasdaq Capital Market under the symbol IMA.
Investors can also locate neBio’s registration statement on Form S-1, which contains detailed descriptions of the company’s business, risk factors, and financial statements, including discussion of how historical financial data were adjusted to reflect the recapitalization associated with the merger. As the company advances -007 through clinical development, periodic and current reports provide additional insight into research and development spending, corporate structure, and key risk disclosures.
Stock Titan enhances these filings with AI-powered summaries that explain the significance of each document in accessible language. Users can quickly understand the main points of lengthy reports while retaining the option to open the full SEC filing text for deeper review, helping them follow IMA’s regulatory and corporate history with less manual effort.
ImageneBio, Inc. announced that it has agreed to a mutual separation with Erin Butler, its Senior Vice President, Finance & Administration and Principal Accounting Officer, effective March 20, 2026. After that date, she will no longer serve as the company’s Principal Accounting Officer and is expected to receive severance benefits under her existing Severance Rights Agreement.
The board of directors has appointed Bob Lally, age 63, currently Senior Vice President, Finance & Operations, to serve as Principal Accounting Officer effective as of the same date. The filing describes Mr. Lally’s prior senior finance and operations roles at Ikena Oncology, Prevail Therapeutics and Arsanis, and notes he did not enter into any new material agreement, has no family relationships with directors or officers, and is not involved in related-party transactions requiring disclosure.
ImageneBio, Inc., formerly Ikena Oncology, completed its merger with Legacy Inmagene and now operates as a clinical-stage biopharmaceutical company focused on immune and inflammatory diseases. The business centers on IMG-007, a non-depleting anti-OX40 antibody initially developed for moderate-to-severe atopic dermatitis.
Early Phase 1b/2a data in atopic dermatitis showed meaningful and durable responses, including EASI‑75 rates of 54% and EASI‑90 rates of 31% at Week 16 after a four-week IV dosing period, with sustained biomarker improvements across Th1, Th2 and Th17 pathways. A multi-country Phase 2b subcutaneous dose-finding trial in atopic dermatitis is under way, with topline data expected in 2027.
The company sees IMG-007 as a potential “pipeline within a product,” with exploratory work in alopecia areata and possible future indications such as asthma, rheumatoid arthritis and hidradenitis suppurativa. However, the business remains entirely dependent on IMG-007’s success, expects significant ongoing losses, requires substantial additional funding, faces intense competition from established biologics and JAK inhibitors, and has disclosed a material weakness in internal controls over financial reporting.
ImageneBio, Inc. reported fourth quarter and full-year 2025 results and highlighted progress on its lead antibody IMG-007, now in the Phase 2b ADAPTIVE trial for moderate-to-severe atopic dermatitis.
For 2025, license revenue was $800 thousand compared with $3.5 million in 2024, reflecting lower collaboration income. Research and development expenses were $28.5 million and general and administrative expenses were $20.7 million, bringing total operating expenses to $49.3 million.
Net loss for 2025 was $45.3 million versus $36.6 million in 2024, as the company invested in building out operations after a reverse merger with Ikena Oncology and incurred transaction-related costs. Imagene ended 2025 with $135.3 million in cash, cash equivalents, and marketable securities, up from $12.1 million a year earlier, supported by the merger and a concurrent $75.0 million private placement.
ImageneBio, Inc. filed an initial insider ownership report for Benjamin Porter-Brown, who serves as Chief Medical Officer. This Form 3 does not list any share transactions or holdings, but formally registers his status as an officer subject to insider reporting rules.
ImageneBio, Inc. files a prospectus supplement registering 2,508,337 shares of common stock for resale by selling stockholders. The supplement incorporates parts of a Form 8-K dated February 17, 2026 and updates the Prospectus dated September 15, 2025.
The supplement states the last reported sales price was $6.85 per share on February 13, 2026. The Form 8-K disclosed that Steven Hui Wang resigned from the Board effective February 12, 2026, and the Company says his resignation was not due to any disagreement with the Company on operations, policies, practices or strategy.
ImageneBio, Inc. reported that Steven Hui Wang resigned from its Board of Directors, effective immediately on February 12, 2026. The company stated that his resignation was not due to any disagreement with ImageneBio regarding its operations, policies, practices, or strategy. The filing otherwise reflects routine corporate and listing information, including that ImageneBio’s common stock trades on the Nasdaq Capital Market under the symbol IMA.
Imagenebio, Inc. received an amended Schedule 13G showing that Deep Track Capital, Deep Track Biotechnology Master Fund, Ltd., and David Kroin now report zero beneficial ownership of the company’s common stock. Each reporting person lists 0 shares with 0% of the class and no voting or dispositive power. The filing confirms they own 5 percent or less of Imagenebio’s common stock. The ownership calculations use 11,181,672 shares outstanding as of November 3, 2025, as disclosed in Imagenebio’s prior quarterly report.
ImageneBio, Inc. received a Schedule 13G filing showing that Blue Owl Capital Holdings LP beneficially owns 823,785 shares of ImageneBio common stock. This represents 7.37% of the company’s outstanding common shares, based on 11,181,672 shares reported as outstanding as of November 3, 2025.
Blue Owl reports sole voting and dispositive power over all 823,785 shares and no shared power. The firm certifies that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of ImageneBio.
ImageneBio, Inc. has filed a prospectus supplement covering the proposed offer and resale from time to time by selling stockholders of 2,508,337 shares of common stock. The supplement incorporates information from a recent current report that notes Chief Medical Officer Yufang Lu, M.D., Ph.D. has notified the company of her resignation, effective December 31, 2025. The company states that her resignation is not due to any disagreement related to operations, policies or practices. ImageneBio is conducting a search for her replacement, and Dr. Lu is expected to provide transition advisory services after her resignation date. The company’s common stock trades on the Nasdaq Capital Market under the symbol IMA, and last traded at $6.24 per share on December 17, 2025.
Imagenebio, Inc. reported that its Chief Medical Officer, Yufang Lu, M.D., Ph.D., has given notice of her resignation effective December 31, 2025. The company states that Dr. Lu’s decision is not due to any disagreement regarding its operations, policies, or practices, which suggests the change is not driven by internal conflict.
Imagenebio is beginning a search for a new Chief Medical Officer, an important role overseeing its medical and clinical programs. Dr. Lu is expected to provide transition advisory services after her resignation date, helping to maintain continuity in the company’s clinical and medical activities while leadership responsibilities are handed over to her eventual successor.